Morphic Holding (DB:31Y) - Hisse Senedi Fiyatı, Haberler ve Analizler

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

31Y Stoklara Genel Bakış

A biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer.

Şirket hakkında

31Y temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Gelirin yılda 81.51% oranında artması öngörülüyor

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $0 )

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 6.4% oranında düşmesi öngörülüyor

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

+ 1 daha fazla risk

Morphic Holding, Inc. Rakipler

Biotest

XTRA:BIO3

€1.3b

Formycon

XTRA:FYB

€863.4m

Heidelberg Pharma

XTRA:HPHA

€116.5m

Medigene

XTRA:MDG1

€24.3m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Morphic Holding
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$50.00
52 Haftanın En Yüksek Seviyesi	US$52.50
52 Haftanın En Düşük Seviyesi	US$18.50
Beta	1.49
11 Aylık Değişim	0.81%
3 Aylık Değişim	71.23%
1 Yıllık Değişim	8.70%
33 Yıllık Değişim	5.49%
5 Yıllık Değişim	156.15%
Halka arzdan bu yana değişim	145.27%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	31Y	DE Biotechs	DE Pazar
7D	-1.0%	-3.1%	-1.0%
1Y	8.7%	-15.2%	16.1%

Getiri vs. Endüstri: 31Y geçen yıl % -15.2 oranında getiri sağlayan German Biotechs sektörünü aştı.

Getiri vs Piyasa: 31Y geçen yıl % 16.1 oranında getiri sağlayan German Piyasasını aştı.

Fiyat Oynaklığı

Is 31Y's price volatile compared to industry and market?
31Y volatility
31Y Average Weekly Movement	22.9%
Biotechs Industry Average Movement	6.2%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.5%

İstikrarlı Hisse Senedi Fiyatı: 31Y hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: 31Y 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 15% dan 23% a yükseldi.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2014	128	Praveen Tipirneni	www.morphictx.com

Morphic Holding, Inc. Temel Bilgiler Özeti

Morphic Holding'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
31Y temel i̇stati̇sti̇kler
Piyasa değeri	€2.60b
Kazançlar(TTM)	-€163.57m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-15.9x

F/K Oranı

31Y aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
31Y gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$165.93m
Brüt Kâr	-US$165.93m
Diğer Giderler	US$13.90m
Kazançlar	-US$179.83m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-3.58
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

31Y uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

This company listing is no longer active

31Y Stoklara Genel Bakış

Ödüller

Risk Analizi

Morphic Holding, Inc. Rakipler

XTRA:BIO3

€1.3b

XTRA:FYB

€863.4m

XTRA:HPHA

€116.5m

XTRA:MDG1

€24.3m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Eli Lilly and Company (NYSE:LLY) completed the acquisition of Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others.

New major risk - Share price stability

Eli Lilly and Company (NYSE:LLY) entered into an agreement and plan of merger to acquire Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others for $3.2 billion.

Morphic Holding, Inc., Annual General Meeting, Jun 04, 2024

Morphic Therapeutic Appoints Simon Cooper as Chief Medical Officer

Full year 2023 earnings released: US$3.59 loss per share (vs US$1.55 loss in FY 2022)

Recent updates

Eli Lilly and Company (NYSE:LLY) completed the acquisition of Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others.

New major risk - Share price stability

Eli Lilly and Company (NYSE:LLY) entered into an agreement and plan of merger to acquire Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others for $3.2 billion.

Morphic Holding, Inc., Annual General Meeting, Jun 04, 2024

Morphic Therapeutic Appoints Simon Cooper as Chief Medical Officer

Full year 2023 earnings released: US$3.59 loss per share (vs US$1.55 loss in FY 2022)

Insufficient new directors

Morphic Holding, Inc. Announces Chief Executive Officer Changes

Third quarter 2023 earnings released: US$0.73 loss per share (vs US$0.78 loss in 3Q 2022)

Morphic Holdings Inc. Announces Chief Executive Officer, Praveen Tipirneni Suffered an Emergent Medical Event and Taking Medical Leave of Absence

Second quarter 2023 earnings released: US$0.92 loss per share (vs US$0.70 profit in 2Q 2022)

First quarter 2023 earnings released: US$0.90 loss per share (vs US$0.85 loss in 1Q 2022)

Full year 2022 earnings released: US$1.55 loss per share (vs US$2.67 loss in FY 2021)

Morphic Holding, Inc. announced that it expects to receive $29.999954 million in funding

Morphic Therapeutic AnnouncesInitiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative Colitis

Third quarter 2022 earnings released: US$0.78 loss per share (vs US$0.69 loss in 3Q 2021)

Morphic Therapeutic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022

Morphic Therapeutic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022

Second quarter 2022 earnings released: EPS: US$0.70 (vs US$0.77 loss in 2Q 2021)

Morphic Therapeutic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs

Morphic Holding, Inc. Announces Management Appointments

First quarter 2022 earnings released: US$0.85 loss per share (vs US$0.64 loss in 1Q 2021)

Morphic Holding, Inc., Annual General Meeting, Jun 08, 2022

Morphic Therapeutic Announces Management Appointments

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Morphic Holding, Inc. Announces Retirement of Dr. Nilesh Kumar from the Board and Resign as Member of the Board and the Audit and Nominating and Governance Committees

Third quarter 2021 earnings released: US$0.69 loss per share (vs US$0.17 profit in 3Q 2020)

Founder recently bought €3.6m worth of stock

Second quarter 2021 earnings released: US$0.77 loss per share (vs US$0.52 loss in 2Q 2020)

Morphic Holding, Inc.(NasdaqGM:MORF) dropped from Russell 3000E Index

Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 At ECCO'21 Virtual Congress

Founder recently bought €8.7m worth of stock

Independent Director has left the company

First quarter 2021 earnings released: US$0.64 loss per share (vs US$0.56 loss in 1Q 2020)

Morphic Announces Clinical Results Update

Independent Director recently bought €59k worth of stock

Full year 2020 earnings released: US$1.47 loss per share (vs US$2.69 loss in FY 2019)

Revenue misses expectations

Morphic Holding, Inc. Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057

New 90-day high: €68.50

New 90-day high: €28.20

Morphic Expands Research and Development Collaboration with Janssen Through Third Integrin Program

New 90-day high: €27.20

Morphic Holding, Inc. Appoints Martin Edwards to Serve on the Board as A Class II Director

New 90-day high: €25.60

Third quarter 2020 earnings released: EPS US$0.17

Revenue beats expectations

Morphic Announces Presentation of New Data Supporting Development of MORF-057 at UEG Week Virtual 2020

Morphic Therapeutic Announces First Healthy Volunteers Dosed in Phase 1 Clinical Trial of MORF-057

Morphic Holding, Inc.(NasdaqGM:MORF) dropped from Russell 3000 Value Index